Literature DB >> 2256744

Recurrent cerebral infarction and the antiphospholipid syndrome: effect of intravenous gammaglobulin in a patient with systemic lupus erythematosus.

G Sturfelt1, F Mousa, H Jonsson, O Nived, H Thysell, F Wollheim.   

Abstract

A 23 year old woman with systemic lupus erythematosus and antiphospholipid syndrome developed severe thrombocytopenia (5-10 X 10(9)/l) and cerebral infarction. Treatment with high doses of corticosteroids and cytostatic drugs was not effective. The condition was successfully treated only when three courses of intravenous gammaglobulin at 400 mg/kg daily was added. A clear relation was found between the immunoglobulin infusions and rising platelet counts, whereas an effect on the levels of anticardiolipin antibodies could not be recorded. The findings suggested that the mechanisms responsible may be modification and solubilisation of immune complexes or interference with anticardiolipin binding to platelet membranes, or both.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2256744      PMCID: PMC1004269          DOI: 10.1136/ard.49.11.939

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  17 in total

1.  In vivo reduction of circulating C1q binding immune complexes by intravenous gammaglobulin administration.

Authors:  R Y Lin; S P Racis
Journal:  Int Arch Allergy Appl Immunol       Date:  1986

Review 2.  The spectrum of neurologic disease associated with antiphospholipid antibodies. Lupus anticoagulants and anticardiolipin antibodies.

Authors:  S R Levine; K M Welch
Journal:  Arch Neurol       Date:  1987-08

3.  Phospholipid antibodies in cardiovascular disease.

Authors:  R Norberg; J Ernerudh; A Hamsten; A M Unander; L Arfors
Journal:  Acta Med Scand Suppl       Date:  1987

4.  The anticardiolipin syndrome.

Authors:  G R Hughes; N N Harris; A E Gharavi
Journal:  J Rheumatol       Date:  1986-06       Impact factor: 4.666

5.  High-dose intravenous intact IgG infusion in refractory autoimmune hemolytic anemia (Evans syndrome).

Authors:  H Oda; A Honda; K Sugita; A Nakamura; H Nakajima
Journal:  J Pediatr       Date:  1985-11       Impact factor: 4.406

6.  Chorea in systemic lupus erythematosus and "lupus-like" disease: association with antiphospholipid antibodies.

Authors:  R A Asherson; R H Derksen; E N Harris; B N Bouma; A E Gharavi; L Kater; G R Hughes
Journal:  Semin Arthritis Rheum       Date:  1987-05       Impact factor: 5.532

7.  Anticardiolipin antibodies in patients with systemic lupus erythematosus.

Authors:  G Sturfelt; O Nived; R Norberg; R Thorstensson; K Krook
Journal:  Arthritis Rheum       Date:  1987-04

8.  Association of lupus anticoagulant with severe valvular heart disease in systemic lupus erythematosus.

Authors:  P M Ford; S E Ford; D P Lillicrap
Journal:  J Rheumatol       Date:  1988-04       Impact factor: 4.666

9.  Systemic lupus erythematosus and infection: a controlled and prospective study including an epidemiological group.

Authors:  O Nived; G Sturfelt; F Wollheim
Journal:  Q J Med       Date:  1985-06

10.  Modification of immune complexes deposited in glomeruli in tissue sections treated with sulfonized gamma-globulin.

Authors:  M Sato; H Kojima; S Koshikawa
Journal:  Clin Exp Immunol       Date:  1986-06       Impact factor: 4.330

View more
  1 in total

Review 1.  Treatment of the antiphospholipid syndrome.

Authors:  J C Piette; M Karmochkine; T Papo; L T Du; C Francès; B Wechsler
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.